#None #Pittsburgh #Frost & Sullivan #MolecuLight #Wound Imaging

MolecuLight Celebrates Recognition as 2026 Global Company of the Year

MolecuLight, a leader in the wound imaging industry, proudly announces that it has been named Frost & Sullivan's 2026 Global Company of the Year. This prestigious award underscores the company's outstanding contributions toward advancing objective wound assessment and enhancing patient outcomes through innovative imaging technology.

Highlights of MolecuLight’s Achievements

Underlining the recognition are several key accomplishments that exemplify MolecuLight's impact and leadership in the field. The award emphasizes the integration of bacterial fluorescence imaging alongside digital wound measurement and thermal imaging into a convenient handheld platform. This unique capability allows clinicians to identify bacterial loads that might not be visible through traditional assessments, thereby significantly improving treatment strategies.

The benefits of this advanced imaging technology are critically important in a medical landscape where timely and accurate data can lead to more effective interventions. MolecuLight's solutions not only enable healthcare professionals to track wounds more accurately but also facilitate better continuity of care through EHR connectivity. This ensures that documentation is both efficient and secure, a commitment further reinforced by the company's SOC 2 Type II and FIPS certifications.

Clinical Evidence and Improved Outcomes

Frost & Sullivan's evaluation highlighted crucial clinical evidence backing the efficacy of MolecuLight's technologies. Numerous studies illustrate how fluorescence-guided care contributes to improved wound healing rates, decreases the need for antibiotics, and leads to fewer complications from infections. This reflects a commitment not just to product development but to enhancing overall patient care.

Anil Amlani, the Chief Executive Officer of MolecuLight, stated, “This recognition reflects our dedication to providing clinicians with objective information that enhances care for patients with wounds. By integrating clinically validated imaging with practical workflows, education, and ongoing support, we empower care teams to make informed treatment decisions that lead to better healing outcomes.”

Commitment to Excellence

The Frost & Sullivan Company of the Year recognition stems from a comprehensive assessment that evaluates organizations based on innovation, performance, and customer impact. MolecuLight's ability to blend cutting-edge technology with a focus on customer support and training has established it as a frontrunner in the healthcare domain.

The commitment extends beyond just technological advancements; MolecuLight prides itself on comprehensive training programs and exceptional customer support. This ensures that clinical teams are well-equipped to utilize the technology successfully,
additional benefit during patient treatment.

About MolecuLight

Established as a privately held medical imaging company, MolecuLight focuses on creating state-of-the-art point-of-care wound imaging devices. Its FDA-cleared systems, MolecuLight iX® and DX®, offer real-time detection of elevated bacterial levels and precise wound measurements. In addition, the MolecuLightDX+® adds thermal imaging to its feature set, reinforcing the company’s commitment to comprehensive wound management. These technologies are well-supported by over 115 peer-reviewed publications that validate their clinical utility and effectiveness.

Conclusion

MolecuLight's prestigious award from Frost & Sullivan illustrates the company's ongoing commitment to advancing wound imaging and improving patient outcomes. As the healthcare landscape continues to evolve, MolecuLight stands poised to drive further innovation in wound care, ensuring that clinicians have the necessary tools to enhance patient healing and overall recovery.